Biopharma | May 20, 2026
IGI’s new drug candidate ISB 2301 to target solid tumors
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Collaboration with Siddhi Diagnostics combines genomics and advanced imaging capabilities to strengthen precision diagnostics in high-growth suburban markets
Discussions during the meeting focused on strengthening India’s preparedness against zoonotic diseases and climate-sensitive health challenges
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
Subscribe To Our Newsletter & Stay Updated
